TianeptineBanned Substance

• In the United States the legal problem arrives before the pharmacology. Tianeptine is not FDA-approved for any medical use, does not meet the statutory definition of a dietary ingredient, and is not generally recognized as safe in food [1].
  
  Selling it as a supplement is therefore unlawful whatever the bottle says. It is marketed anyway as a "research chemical", a nootropic, or a dietary supplement [1]. ^[1]

• What the FDA and DEA point to is a harm record, not a paperwork gap [1].
  
  Both cite rapidly rising poison-control calls, seizures, coma, respiratory depression and deaths, plus high abuse and dependence potential from tianeptine's mu-opioid receptor agonism [1].
  
  The DEA and HHS eight-factor analyses concluded its pharmacological effects resemble those of Schedule II opioids, naming morphine and fentanyl as the comparators [4]. ^[4]

• Whether tianeptine is "banned" depends on which law you mean, and on the date. As of the DEA's own May 2026 fact sheet it was still not federally controlled under the Controlled Substances Act [5].
  
  The DEA published a proposed rule on July 8, 2026 to place it in Schedule I, with the public comment period closing August 7, 2026 [4]. That rulemaking was pending, not in effect.
  
  Meanwhile at least 15 states had already banned or scheduled it under their own laws [4]. Federal and state answers genuinely differ here, and we are not flattening them into one. ^[4]

• Alongside its glutamatergic antidepressant activity, tianeptine is a full mu-opioid and weak delta-opioid receptor agonist [13].
  
  That is why an overdose reads as an opioid overdose, and why stopping abruptly reads as opioid withdrawal [13]. ^[13]

• The CDC analyzed 218 US poison-control calls for tianeptine exposure between 2000 and 2017 [3].
  
  Among tianeptine-only exposures, neurologic effects led at 48.3% — agitation 21.9%, drowsiness 16.7%, confusion 13.2%, coma 4.4% [3].
  
  Cardiovascular effects followed at 32.5%, mostly tachycardia (25.4%) and raised blood pressure (11.4%). Gastrointestinal effects appeared in 10.5% [3]. ^[3]

• The deaths are the part the CDC dataset missed. Among 93 tianeptine-only exposures with a known outcome, 54% were classed moderate and none were fatal [3].
  
  That surveillance window predates several documented US fatalities. Two Texas cases had postmortem blood concentrations of 2.0 mg/L and 8.4 mg/L [7].
  
  A separate case series reported fatal serum concentrations of 4,000–18,000 ng/mL, against a reference therapeutic range near 278–366 ng/mL [6].
  
  The "no deaths" finding reflects a voluntary reporting system with gaps, not an absence of fatal cases [7]. ^[7]

• The FDA's own tally shows annual US poison-control cases involving tianeptine climbing from about 4 in 2013 to roughly 350 in 2024 [12]. ^[12]

• Repeated use readily produces dependence, and withdrawal mimics opioid withdrawal [8].
  
  Reported features include agitation, nausea, vomiting, diarrhea, tachycardia, raised blood pressure, tremor, sweating, and in some cases myoclonic jerking [3].
  
  Some cases have been severe enough to require intubation or benzodiazepine sedation [8]. ^[8]

• A published case report links maternal tianeptine dependence during pregnancy to neonatal abstinence syndrome in the newborn, resembling opioid withdrawal [19].
  
  The mother had been using more than 650 mg/day, against a normal prescribed dose of roughly 25–50 mg/day [19]. The infant was managed with morphine. ^[19]

• Michigan was among the first states to restrict tianeptine, in 2018 — the same year the CDC published its first poison-control surveillance report on it [3].
  
  Oklahoma followed in 2019, Alabama in 2021, then Arkansas, Ohio and Tennessee in 2022 [4]. ^[4]

• Florida, Kentucky, Minnesota and Mississippi added their own scheduling in 2023 [4].
  
  Federal escalation ran through one product line, Neptune's Fix. A consumer warning came on November 21, 2023, after reports of seizures and loss of consciousness [2]. ^[2]

• On January 11, 2024 the FDA wrote to convenience stores and gas stations urging them to stop selling tianeptine products [2].
  
  Adverse-event reports including a death were noted on January 23, and Neptune Resources LLC announced a voluntary nationwide recall on January 28, 2024 [1].
  
  A second distributor, Super Chill Products, recalled on February 15, 2024, alongside Justice Department criminal sentencing announcements for tianeptine trafficking [2]. ^[2]

• Georgia, Indiana, Louisiana, Maryland and Virginia added state-level scheduling in 2024 [4].
  
  On May 8, 2025 the FDA issued a letter to health-care providers flagging a new "gas station heroin" product trend [1].
  
  That letter described case reports of consumers taking 1.3 to 250 times the therapeutic foreign daily dose — roughly 50 mg to 10,000 mg [2]. ^[1]

• The federal scheduling track has run slower than the state one. The DEA requested an HHS scientific and medical evaluation on September 7, 2023 [4].
  
  HHS delivered a Schedule I recommendation on July 18, 2025, and the DEA published its proposed rule on July 8, 2026 [4].
  
  The comment period closed August 7, 2026. As of the DEA's May 2026 fact sheet, tianeptine remained federally uncontrolled [5]. ^[4]

• Outside the US, tianeptine has been banned or controlled in Bahrain (2003), Russia (2010), Ukraine (2011), Turkey (2012) and Italy (2020) [4]. ^[4]

No official lethal dose exists for tianeptine, and none of the sources here offers one [2].

Published cases almost always involve unregulated, mislabeled products and other drugs taken alongside. Every figure below is a case-based reference point, not a cutoff.

Where tianeptine is an approved antidepressant, the daily dose is roughly 25–50 mg/day, often 12.5 mg three times daily [16]. That corresponds to a serum range near 278–366 ng/mL [6].

FDA-reviewed case reports describe US consumers of illicit products taking 1.3 to 250 times that amount — roughly 50 mg to 10,000 mg per use [2].

A case series linked fatal outcomes to serum concentrations of 4,000–18,000 ng/mL [6]. Two confirmed US fatalities had postmortem blood concentrations of 2.0 mg/L and 8.4 mg/L [7].

In the reported neonatal abstinence case, the mother had been using more than 650 mg/day [19].

The pharmacokinetics complicate the picture. Tianeptine itself has a half-life near 2.5 hours and 90–99% oral bioavailability, but its active mu-opioid metabolite MC5 runs 7.2–12.3 hours [4].

Toxicity can therefore outlast what the parent compound's short half-life would suggest [4].

The sources do not converge on one dangerous amount. Forensic case reports, the DEA and HHS scheduling review, and the poison-control literature all report overlapping but non-identical ranges [2]. ^[2]

If someone who has taken tianeptine is unresponsive, hard to wake, or struggling to breathe, call 911 immediately [9].

Give bystander naloxone if it is on hand. Tianeptine's mu-opioid activity means naloxone can partly restore breathing and alertness, though the response is sometimes incomplete and repeat dosing may be needed [9].

For a milder exposure — someone alert, breathing normally — the free webPOISONCONTROL tool or a poison center on 1-800-222-1222 is the route [9]. Guidance there is free, confidential and available 24/7 [9].

In the emergency department, care is supportive: airway and breathing monitoring with oxygen as needed, IV fluids for low blood pressure, and continuous cardiac monitoring with a 12-lead ECG [11].

Tianeptine can produce sodium-channel-blockade cardiac effects, which are managed with sodium bicarbonate [11]. Naloxone is given for the opioid-like sedation and respiratory depression [11].

In the CDC dataset, the therapies most often administered for tianeptine-only exposures were IV fluids (35.1%), benzodiazepines (27.2%), oxygen (10.5%) and naloxone (9.7%) [3].

One diagnostic trap matters more than the rest. Tianeptine does not show up on routine urine drug screens or standard toxicology panels, so a negative result does not rule it out [9].

Confirming it takes specialized LC-MS/MS testing, so clinicians often work from history instead — pill bottles, or an account from friends and family [11].

Withdrawal is managed symptomatically, using benzodiazepines, alpha-2 agonists such as clonidine, antipsychotics, or barbiturates for agitation [11]. Buprenorphine has been used in a small number of reported cases [11]. ^[9]